| Mon, Nov 9, 2009 | | • | Mentor Capital Growth Continues as Lead Investee Adds New Cancer Lab, Filings and Collaborators
Business Wire (Mon, Nov 9)
| | Fri, Oct 30, 2009 | | • | Mentor Capital, Inc. Rated a $5/sh Speculative Buy on Immune System Breast Cancer Treatment in FDA Phase I/II Trials
Business Wire (Fri, Oct 30)
| | Tue, Oct 20, 2009 | | • | Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter
Business Wire (Tue, Oct 20)
| | Wed, Sep 30, 2009 | | • | Mentor Capital, Inc. Speaks on Cancer Investment with Long Island Investment Banking Group
Business Wire (Wed, Sep 30)
| | Mon, Sep 21, 2009 | | • | Mentor Capital, Inc. Completes 2nd Year Audit for OTCBB Move; Reporting $0.16 Per Share in Basic Earnings
Business Wire (Mon, Sep 21)
| | Wed, Sep 16, 2009 | | • | Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead by ImmunoCellular Therapeutics
Business Wire (Wed, Sep 16)
| | Fri, Aug 28, 2009 | | • | New Cancer Immunotherapy Index Posts 23% Gains Lead by Mentor Capital, Inc. and Oncothyreon
Business Wire (Fri, Aug 28)
| | Thu, Jul 16, 2009 | | • | Quantum Immunologics Achieves Major Funding in Support of Ongoing FDA Trials
Marketwire (Thu, Jul 16)
| | Wed, May 27, 2009 | | • | Mentor Capital, Inc. Portfolio Outperforms DOW by a 31.4% Rate
GlobeNewswire (Wed, May 27)
|
Add MNTR.PK News to My Yahoo!:
 
| |
|
1.31% Nasdaq 
0.02 (1.33%) 
Headlines
